The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

Epitalon

AEDG · Epithalon

C
Animal replicated
BioregulatorTetrapeptideBioregulatorTelomerase Modulator
RouteInjectableGray-market only
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
Ala-Glu-Asp-Gly — Synthetic Pineal Tetrapeptide (AEDG) — Tetrapeptide, Bioregulator, Telomerase Modulator.
Why people use it
Sleep Quality and Melatonin Restoration · Anti-Aging and Longevity · Telomere Lengthening · Anti-Tumor Effects · Retinal and Ocular Effects · Bovine Oocyte Maturation
What the evidence supports
No human RCT exists for any indication. 'Human clinical data' cited in the literature consists of: (1) open-label non-randomized observations from Khavinson's institute in elderly patients; (2) studies using Epithalamin (the complex extract), not pure Epitalon; (3) mortality data from historical comparator designs, not controlled trials. This is substantially weaker than the framing 'decades of human clinical data' implies.
If you only read one thing

Epitalon has more published research behind it than almost any other compound in the longevity peptide space — 40+ years, multiple species, multiple tissue types, telomerase activation, lifespan extension in animals, melatonin restoration in humans. It also has the most concentrated provenance of any compound in this reference: essentially all of this research comes from one man and one institute, for whom the compound's success is directly tied to their scientific legacy and institutional mission. The first meaningful independent Western replication of the central telomerase claim appeared in 2025 — 22 years after Khavinson published it. That gap is not evidence the compound doesn't work. It is evidence that the evidence has not been stress-tested by adversarial independent replication in the way that science requires for high confidence. 40 years of internally consistent research from one source is not the same as 40 years of independent replicated science. Both descriptions of the evidence are technically accurate. Only one of them is scientifically precise.

Check interactions →
Route / form

Same compound, route-specific context. Switch forms instead of opening separate pages.

Evidence fit
Route-specific

Use the route notes below to match form, goal, and evidence quality.

Route caveat
Protocol not standardized

No route-matched protocol rows were parsed for this form; use the route notes and full dosing chapter before comparing options.

Protocol anchor
Full dosing section

Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.

Typical dose snapshot
See route notes
Evidence varies by use case
Published literature
0human trials3human studies5animal3in vitro

Human evidence is non-randomized/open-label or Epithalamin-derived; no RCT of pure Epitalon for any indication.

Evidence reality check
Human evidence
3 human studies
3 observational; RCT evidence not present in corpus.
Preclinical base
8 lab signals
5 animal; 3 in-vitro/mechanistic.
Evidence snapshot
No human RCT exists for any indication. 'Human clinical data' cited in the literature consists of: (1) open-label non-randomized observations from Khavinson's institute in elderly patients; (2) studies using Epithalamin (the complex extract), not pure Epitalon; (3) mortality data from historical comparator designs, not controlled trials. This is substantially weaker than the framing 'decades of human clinical data' implies.
From the chapter quick-reference block.
Indication map
Supported / plausible / speculative / avoid
Plausible
Sleep Quality and Melatonin Restoration · Anti-Aging and Longevity · Telomere Lengthening · Anti-Tumor Effects · Retinal and Ocular Effects · Bovine Oocyte Maturation
No human RCT exists for any indication. 'Human clinical data' cited in the literature consists of: (1) open-label non-randomized observations from Khavinson's institute in elderly patients; (2) studies using Epithalamin (the complex extract), not pure Epitalon; (3) mortality data from historical comparator designs, not controlled trials. This is substantially weaker than the framing 'decades of human clinical data' implies.

Epitalon is the compound in this reference where the research history is longest, the provenance problem is most acute, and the gap between what the community believes and what the evidence actually shows is widest. Forty years of research is remarkable. The fact that nearly all of it comes from one scientist and one institution is the defining caveat.

The central tension resolved: Vladimir Khavinson discovered Epitalon, synthesized Epitalon, studied Epitalon, published on Epitalon, continues to publish on Epitalon, and leads the institution that holds commercial interest in Epitalon-related compounds. This is not a disqualification — every compound starts with a developer. But it is a limitation that compound science is designed to address through independent replication. Selank's Russian approval, reviewed in this reference, came from two independent Russian institutions. Semax has Dolotov 2006 — an independent researcher confirming the BDNF finding. Epitalon's central claim — the one the entire longevity community is excited about — went 22 years without a meaningful independent attempt at replication. The Al-Dulaimi 2025 paper is a positive development. One paper from one independent group, 22 years later, confirming telomere elongation in cancer cell lines, is not the same as an established evidence base.

The strongest argument for Epitalon: it is the most mechanistically interesting longevity compound in this reference from a pure biology perspective. Telomerase activation by a four-amino acid peptide, if the mechanism is real and generalizable, represents a genuinely elegant biological insight. The pineal/melatonin mechanism is well-supported and has a clear human application (sleep quality in aging). The animal data is consistent across species. The safety profile is genuinely clean. The compound has been studied for longer than any other in this reference. And the 2025 wave of independent publications (Al-Dulaimi, Gatta, bovine oocyte) suggests the field is finally receiving the independent attention it has long deserved.

The strongest argument for caution: the evidence architecture is structurally fragile. One motivated researcher, one institution, 40 years of internally consistent data, one independent replication. The human 'clinical data' is non-randomized, single-institution, uses a different compound (Epithalamin), and was generated by the same people who developed and commercialize the compound. The most exciting claim — telomere elongation in living humans — has never been tested in a controlled trial. The PCAC review is for insomnia, not longevity, reflecting the FDA's appropriately conservative reading of what the evidence actually supports.

Categories
Cognition & MoodSleep & RecoveryLongevity & Anti-aging
Properties
Active malignancy: hard stop✓ Human evidenceSingle-lab provenanceNot injectable
Molecular weight
~390 Da (C14H22N4O9). Four amino acids: Alanine-Glutamic acid-Aspartic acid-Glycine. One of the smallest pharmacologically active peptides studied for longevity.
Evidence
CAnimal replicated
Names / Spellings
Epitalon = Epithalon = Epithalone. All the same compound: the tetrapeptide Ala-Glu-Asp-Gly (AEDG). NOT the same as Epithalamin — see Section 2.4 for the critical distinction.
Origin
Developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in the 1980s. Derived from Epithalamin — a bovine pineal gland polypeptide extract.
THE PROVENANCE PROBLEM
Essentially the entire published evidence base for Epitalon originates from one institution: the St. Petersburg Institute of Bioregulation and Gerontology, led by Vladimir Khavinson. Khavinson has published extensively on Epitalon for over 40 years and remains the primary author on papers published in 2024-2025. The first significant independent Western replication of the telomerase activation claim was Al-Dulaimi et al. (Biogerontology, 2025). That is 22 years between the headline finding and the first independent attempt to replicate it. This is the defining limitation of the Epitalon evidence base.
Primary Mechanisms
Telomerase (hTERT) activation in human somatic cells (in vitro); pineal gland stimulation → melatonin restoration; antioxidant enzyme upregulation; gene expression modulation via DNA/histone H1 binding.
Telomere Claim (In Vitro)
Khavinson et al. 2003: Epitalon activated telomerase in human fetal lung fibroblasts; treated cells exceeded the Hayflick limit. Al-Dulaimi et al. 2025: independent partial replication — telomere elongation confirmed in human cancer cell lines via both telomerase upregulation and ALT activity. Critical: this is cell culture data. Whether SubQ Epitalon injection produces meaningful telomere elongation in living humans has never been demonstrated in a controlled trial.
Animal Lifespan Data
12-24% lifespan extension in rodents (Khavinson group). 16% in Drosophila. Some independent corroboration in oncology models (Anisimov). Grade C: consistent animal data; Khavinson provenance dominant.
Community Dosing
5-10 mg/day SubQ or nasal spray, 10-20 consecutive days, 2-3 times per year (cyclic, not continuous). Some protocols use lower doses. Nasal spray is widely used — convenience-driven, not evidence-based.
FDA / Regulatory 2026
Category 2 removed April 22, 2026. PCAC review July 24, 2026 for the insomnia indication (the sleep/melatonin application — not telomere/anti-aging). The FDA's framing of Epitalon is as a sleep compound, not a longevity compound.
WADA
Not explicitly listed on the 2026 WADA Prohibited List. Not covered by any S0-S5 category. Athletes can currently use Epitalon without known WADA violation. Verify current status before competition use.
Safety
Clean profile across published studies. No serious adverse events documented. Most common: mild injection site reactions. Long-term safety beyond published study durations not characterized. No significant drug interactions identified.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
Pinealon
C
Same class · Bioregulator

Short Khavinson tripeptide positioned for brain and pineal-gland bioregulation. The appeal is cognitive aging, neuroprotection, and circadian support; the limitation is that the evidence is mostly single-institution preclinical work, not human clinical validation.

Khavinson Bioregulator Cluster
C
Same class · Bioregulator

Four Organ-Specific Bioregulators from the Russian Khavinson Research Tradition. The Theory That Short Peptides Regulate Gene Expression in a Tissue-Specific Way. Cortexin: A Russian-Approved Neuroprotective Extract with Multi-Receptor Activity. CardioCytogen (Ala-Glu-Asp-Arg): The Cardiac Fibroblast Modulator. Crystagen: Connective Tissue and Cartilage Bioregulator. Bronchogen: Pulmonary Bioregulator Tetrapeptide. The Shared Evidence Architecture That Applies to All Four.

Khavinson Bioregulators
C
Same class · Bioregulator

40+ Years of Russian Research. 500+ Publications. One Institution. The Most Concentrated Single-Lab Provenance of Any Compound Class in this reference. Vladimir Khavinson (1946-2024) and the St. Petersburg Institute of Bioregulation and Gerontology. The Epigenetic Chromatin Mechanism. The Cytomax vs Cytogen Distinction. The 6-to-8-Year Mortality Study. The 2025 Independent Replication That Changed the Evidence Conversation. 14 Organ-Specific Bioregulators — Their Sequences, Targets, Evidence, and Protocols.

Check interactions